Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Condition:   KRAS Gene Mutation Intervention:   Drug: TVB-2640 Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting

Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials